Indian pharmaceutical intermediate and API manufacturer Hikal Limited (Hikal Limited) announced on June 19 that it has successfully developed Favipiravir API and its intermediates.
Fapiravir is a generic drug of Avigan, a drug of Toyama Chemical, a subsidiary of Fujifilm Corporation in Japan. The drug has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of new influenza virus infections. At present, in many countries, piravir is in different stages of clinical trials for the treatment of new coronavirus pneumonia.
It is reported that Hikal is negotiating with potential partners on the supply of the finished medicine.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Pressure on the Asian ethylene glycol market is difficult to eliminate
What is the reason behind the feed increase three times in three months?
The EU issued a formal ban on lambda-cyfluthrin
China's fertilizer exports fell by 5%
China's foreign trade volume rises 6.5% to 3t yuan
Market trend of waterborne building waterproof coatings